RTTNews | May 29, 2021 12:40AM EDT

00:39 Saturday, May 29, 2021 (RTTNews.com) - CureVac N.V. (CVAC) said that the independent Data Safety Monitoring Board or DSMB has confirmed that the pivotal Phase 2b/3 study, dubbed as HERALD, for the company's first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases.

The DSMB confirmed that there were no safety concerns for CVnCoV. The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis.

The HERALD trial is conducted in an environment characterized by the spread of multiple virus strains. COVID-19 cases within the trial are currently being sequenced to provide critical complementary data to the efficacy readout.

The HERALD study has enrolled about 40,000 participants in ten countries in Latin America and Europe. The primary objective of the HERALD study is to demonstrate the efficacy of a two-dose administration of 12g of CVnCoV in preventing COVID-19 infection of any severity in participants without prior exposure to SARS-CoV-2.

Read the original article on RTTNews ( https://www.rttnews.com/3198490/curevac-says-covid-19-vaccine-passed-first-analysis.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved